Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 14
- CBD Market
‘Flawed’ CBD Safety Advice Costs Industry Millions of Pounds In ‘Unnecessary’ Animal Tests
THE CBD industry is being failed by ‘unnecessary’ ‘unethical’ and ‘unscientific’ directions from the UK regulators, claim the authors of a new report.
- Pharmaceutical
Further drug development agreement for Oxford Cannabinoid Technologies
Dalriada will support the company with R&D activities.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings Signs New Agreement With Dalriada Drug Discovery
Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”, together, the “Group”), a company developing licensed prescription cannabinoid medicines for approval by regulatory agencies worldwide and targeting the U$ multi-billion pain market, is pleased to announce that OCT has signed an important new drug development agreement with Dalriada.
- Pharmaceutical
Oxford Cannabinoid Technologies Signs New Agreement With Stemtech
OCT believes Stemtech’s technology provides an in vitro translational model that will better predict results in humans.
- Pharmaceutical
Oxford Cannabinoid Technologies signs drug development programme
The company has signed a new agreement with Oxford-based StemTech.
- Pharmaceutical
Cannabis Europa – ‘A Melting Pot Of Ideas And Conversations’ – Makes A Successful London Return
STEPHEN Murphy, co-founder and CEO of Prohibition Holdings, kicked-off Cannabis Europa 2021 in central London’s Banking Hall yesterday, welcoming delegates from across Europe and North America, Africa, Asia and Australia.
- Pharmaceutical
Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach
THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules.
- Pharmaceutical
UK Cannabis Company’s C-Suite Left ‘Shaking Their Heads’ In Disbelief At Company’s Poor Stock Performance
FOLLOWING its listing on the London Stock Exchange in May this year Oxford Cannabinoid Technologies (OCT) has seen more than £20m wiped off its market capitalisation.
- CBD Market
Cannabis will be ‘stronger’ post-Covid: CNN
The cannabis industry is thriving, according to a CNN report from last week’s MJ BizCon event in Las Vegas, and could be one of the few industries that’s stronger post-pandemic.
- Pharmaceutical
Oxford Cannabinoid Technologies expects to list on OCT QB in November
Harbour Access has been appointed as North American investor relations advisor to provide support for the listing.
- Pharmaceutical
Melissa Sturgess: “You can’t change the rules standing on the sidelines”
CEO of Ananda Developments, Melissa Sturgess, discusses how she is taking on the cannabis industry.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings New Partnerships Targeting Trigeminal Neuralgia
OXFORD Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (OCT), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the US$ multi-billion pain market, announces the signing of new partnerships to target trigeminal neuralgia (TN) – an increasingly prevalent chronic pain condition.
